United Kingdom (UK)
Recombinant monoclonal antibody to E2a protein. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 5B4D-6.
UniProt Accession Number of Target Protein: P05674
Alternative Name(s) of Target: VEEV E2a; Envelope glycoprotein E2; Structural polyprotein; Envelope glycoprotein E2; Spike glycoprotein E2; Alphavirus; TC-83 virus; D66
Immunogen: The original antibody was generated by immunizing BALB/c mice with TC-83 vaccine strain of Venezuelan equine encephalomyelitis virus (VEEV).
Specificity: This antibody specifically binds the E2a epitope of the envelope glycoprotein of the Venezuelan equine encephalitis virus (VEEV), member of the family Togaviridae, genus Alphavirus. VEEV is a mosquito-borne viral pathogen that causes Venezuelan equine encephalitis or encephalomyelitis (VEE). VEE is a disease endemic in regions of Central and South America that causes sporadic outbreaks of equine and human encephalitis. VEEV can affect equine species, such as horses, donkeys, and zebras.
Application Notes: The binding characterization of this antibody towards Venezuelan equine encephalomyelitis virus strain TC-83 was done using ELISA (PMID: 6178209). This antibody was also used for an indirect immunofluorescence assay for the detection of VEEV in virus-infected Vero cells (PMID: 2037683).
Antibody first published in:
Roehrig et al. Antigenic analysis of the surface glycoproteins of a Venezuelan equine encephalomyelitis virus (TC-83) using monoclonal antibodies. Virology. 1982 Apr 30;118(2):269-78. PMID:6178209
Note on publication:
Describes the characterization of antigenic proteins on the surface of Venezuelan equine encephalomyelitis virus (TC-83) using antibodies.